Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Offidani

Showing results (21-30 of 149) with videos related to

Pageof 15
Sort By:
Expert Review of Anticancer Therapy|April 18, 2014
Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical dataMassimo Offidani, Laura Corvatta, Patrizia Caraffa, et al.
Current Cancer Drug Targets|September 24, 2016
Stem Cell Transplantation in Multiple MyelomaMassimo Offidani, Silvia Gentili, Francesca Gay, et al.
Frontiers in Oncology|March 8, 2021
Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging TreatmentsMassimo Offidani, Laura Corvatta, Sonia Morè, et al.
Experimental Hematology|June 26, 2007
A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patientsAttilio Olivieri, Debora Capelli, Emanuela Troiani, et al.
Expert Opinion on Investigational Drugs|July 4, 2015
Ixazomib for the treatment of multiple myelomaMassimo Gentile, Massimo Offidani, Ernesto Vigna, et al.
Cells|February 25, 2022
Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?Sonia Morè, Laura Corvatta, Valentina Maria Manieri, et al.
Oncotarget|October 22, 2016
Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migrationMassimo Nabissi, Maria Beatrice Morelli, Massimo Offidani, et al.
Expert Opinion on Pharmacotherapy|February 10, 2015
Smoldering multiple myeloma: to treat or not to treatMassimo Gentile, Massimo Offidani, Ernesto Vigna, et al.
Critical Reviews in Oncology/Hematology|February 13, 2022
Management of infectious risk of daratumumab therapy in multiple myeloma: A consensus-based position paper from an ad hoc Italian expert panelCorrado Girmenia, Michele Cavo, Alessandro Corso, et al.
Cancer|July 27, 2004
Risk assessment of patients with hematologic malignancies who develop fever accompanied by pulmonary infiltrates: a historical cohort studyMassimo Offidani, Laura Corvatta, Lara Malerba, et al.
Pageof 15

Showing results (21-30 of 149) with videos related to

Sort By:
Pageof 15
Expert Review of Anticancer Therapy|April 18, 2014
Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical dataMassimo Offidani, Laura Corvatta, Patrizia Caraffa, et al.
Current Cancer Drug Targets|September 24, 2016
Stem Cell Transplantation in Multiple MyelomaMassimo Offidani, Silvia Gentili, Francesca Gay, et al.
Frontiers in Oncology|March 8, 2021
Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging TreatmentsMassimo Offidani, Laura Corvatta, Sonia Morè, et al.
Experimental Hematology|June 26, 2007
A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patientsAttilio Olivieri, Debora Capelli, Emanuela Troiani, et al.
Expert Opinion on Investigational Drugs|July 4, 2015
Ixazomib for the treatment of multiple myelomaMassimo Gentile, Massimo Offidani, Ernesto Vigna, et al.
Cells|February 25, 2022
Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?Sonia Morè, Laura Corvatta, Valentina Maria Manieri, et al.
Oncotarget|October 22, 2016
Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migrationMassimo Nabissi, Maria Beatrice Morelli, Massimo Offidani, et al.
Expert Opinion on Pharmacotherapy|February 10, 2015
Smoldering multiple myeloma: to treat or not to treatMassimo Gentile, Massimo Offidani, Ernesto Vigna, et al.
Critical Reviews in Oncology/Hematology|February 13, 2022
Management of infectious risk of daratumumab therapy in multiple myeloma: A consensus-based position paper from an ad hoc Italian expert panelCorrado Girmenia, Michele Cavo, Alessandro Corso, et al.
Cancer|July 27, 2004
Risk assessment of patients with hematologic malignancies who develop fever accompanied by pulmonary infiltrates: a historical cohort studyMassimo Offidani, Laura Corvatta, Lara Malerba, et al.
Pageof 15